Novartis AG
NVSHealthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −68.8%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $15.7B covered $15.3B of dividends and buybacks. Cash fell by $686.0M. Lines the picture does not name came to −$5.4B. What is a cash flow statement?
- Free cash flow
- $15.7B 90.6% of operating cash flow
- Returned to shareholders
- $15.3B 97.5% of free cash flow
- Debt, net
- $16.2B borrowed
- Change in cash
- −$686.0M over the period
| Operating cash flow | 17.3 |
|---|---|
| Capital expenditures | −1.6 |
| Free cash flow | 15.7 |
| Acquisitions, net | −12.7 |
| From investments, net | +0.9 |
| Dividends | −9.1 |
| Buybacks, net | −6.2 |
| Debt raised, net | +16.2 |
| Other | −5.4 |
| Change in cash | −0.7 |
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $19.1B | $19.2B | $18.4B | $17.3B |
| Capex | −$1.5B | −$1.6B | −$1.6B | −$1.6B |
| Free cash flow | $17.6B | $17.5B | $16.8B | $15.7B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
10,013.00 | 12,747.00 | 13,514.00 | 13,967.00 |
+8 more TTM periods Free account |
Depreciation & Amortization |
7,693.00 | 5,442.00 | 5,288.00 | 5,275.00 | |
Non Cash Items (Other) |
3,205.00 | 2,495.00 | 2,482.00 | 2,962.00 | |
Accounts Receivable Change |
(1,024.00) | (674.00) | (585.00) | (1,124.00) | |
Change in inventories |
118.00 | (42.00) | (116.00) | 34.00 | |
Accounts Payable Change |
(94.00) | (195.00) | (154.00) | (273.00) | |
Change in other assets and liabilities |
(1,197.00) | 105.00 | 259.00 | (214.00) | |
Other operating activities |
(1,496.00) | (1,485.00) | (1,513.00) | (1,483.00) | |
Operating Cash Flow |
17,325.00 | 18,393.00 | 19,175.00 | 19,144.00 | |
Capital expenditures |
(1,636.00) | (1,597.00) | (1,632.00) | (1,535.00) | |
Change in intangibles (net) |
(1,544.00) | (1,619.00) | (1,415.00) | (2,188.00) | |
Net Aquisitions |
(12,741.00) | (11,737.00) | (12,274.00) | (235.00) | |
Short Term Investments Change (Net) |
814.00 | 769.00 | 1,066.00 | 1,781.00 | |
Long-Term Investments Change (Net) |
76.00 | 134.00 | 105.00 | 93.00 | |
Other investing activities |
(3,660.00) | (3,755.00) | (2,793.00) | (2,793.00) | |
Investing cash flow |
(18,691.00) | (17,805.00) | (16,943.00) | (4,877.00) | |
Repayment/Issuance of Debt (Net) |
16,191.00 | 16,448.00 | 14,526.00 | 2,430.00 | |
Equity Repurchase (Common, Net) |
(6,234.00) | (6,836.00) | (8,345.00) | (9,185.00) | |
Dividends Paid (Total) |
(9,068.00) | (9,068.00) | (8,682.00) | (7,818.00) | |
Other financial activities |
(111.00) | (91.00) | (239.00) | (294.00) | |
Financing cash flow |
778.00 | 453.00 | (2,740.00) | (14,867.00) | |
Exchange Rate Adjustment |
(98.00) | (81.00) | 319.00 | 576.00 | |
Change in Cash |
(686.00) | 960.00 | (189.00) | (24.00) | |
Beginning Cash |
11,435.00 | 11,435.00 | 11,435.00 | 11,459.00 | |
Ending Cash |
10,749.00 | 12,395.00 | 11,246.00 | 11,435.00 | |
Stock Based Compensation |
1,136.00 | 1,137.00 | 1,137.00 | 1,096.00 | |
Dividends Paid (Common) |
(9,068.00) | (9,068.00) | (8,682.00) | (7,818.00) | |
Assets Liabilities Change (Total) |
(2,090.00) | (806.00) | (596.00) | (1,577.00) | |
Investments Change (Net) |
890.00 | 903.00 | 1,171.00 | 1,874.00 | |
Issuance/Purchase of Shares |
(6,234.00) | (6,836.00) | (8,345.00) | (9,185.00) |